Eric Benevich, Chief Commercial Officer at Neurocrine Biosciences ($NBIX), made one open market sale of company shares in the last year, totaling about $906,000. His most recent sale occurred on November 28, 2025. With no open market purchases recorded, his sales rank 5,160th out of 11,678 insiders, below the average of $8.6 million per seller and 6.4 transactions.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | A | Stock Option | 36287 | $0.00 | 36,287.0000 | 102,500,000 | 9999.99% | 0.04% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | A | Restricted Stock Unit | 6365 | $0.00 | 6,365.0000 | 102,500,000 | 9999.99% | 0.01% |
| Feb. 12, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 2005 | $0.00 | 54,760.0000 | 102,500,000 | 3.80% | 0.00% |
| Feb. 12, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | F | Common Stock | 1082 | $123.10 | 53,678.0000 | 102,500,000 | 1.98% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 1961 | $0.00 | 55,639.0000 | 102,500,000 | 3.65% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | F | Common Stock | 1058 | $124.12 | 54,581.0000 | 102,500,000 | 1.90% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 2083 | $0.00 | 56,664.0000 | 102,500,000 | 3.82% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | F | Common Stock | 1124 | $124.12 | 55,540.0000 | 102,500,000 | 1.98% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | A | Common Stock | 16613 | $0.00 | 72,153.0000 | 102,500,000 | 29.91% | 0.02% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | F | Common Stock | 8963 | $124.12 | 63,190.0000 | 102,500,000 | 12.42% | 0.01% |
| Feb. 12, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Restricted Stock Unit | 2005 | $0.00 | 6,017.0000 | 102,500,000 | 24.99% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Restricted Stock Unit | 1961 | $0.00 | 3,924.0000 | 102,500,000 | 33.32% | 0.00% |
| Feb. 13, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Restricted Stock Unit | 2083 | $0.00 | 2,083.0000 | 102,500,000 | 50.00% | 0.00% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | F | Common Stock | 1292 | $136.06 | 52,755.0000 | 102,500,000 | 2.39% | 0.00% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 2294 | $0.00 | 54,047.0000 | 102,500,000 | 4.43% | 0.00% |
| Jan. 31, 2026 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Restricted Stock Unit | 2294 | $0.00 | 0.0000 | 102,500,000 | 100.00% | 0.00% |
| Nov. 28, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Incentive Stock Option | 12830 | $0.00 | 0.0000 | 102,500,000 | 100.00% | 0.01% |
| Nov. 28, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 12830 | $35.99 | 109,476.0000 | 102,500,000 | 13.28% | 0.01% |
| Nov. 28, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 5970 | $151.74 | 44,893.0000 | 102,500,000 | 11.74% | 0.01% |
| Nov. 28, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Incentive Stock Option | 5970 | $0.00 | 6,860.0000 | 102,500,000 | 46.53% | 0.01% |
| Nov. 28, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 5970 | $35.99 | 50,863.0000 | 102,500,000 | 13.30% | 0.01% |
| May 1, 2025 | aTYR PHARMA INC | $ATYR | BENEVICH ERIC | Not found | A | Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 88,858,612 | 9999.99% | 0.06% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 1098 | $116.74 | 43,784.0000 | 103,700,000 | 2.45% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Restricted Stock Unit | 1961 | $0.00 | 5,885.0000 | 103,700,000 | 24.99% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Restricted Stock Unit | 2083 | $0.00 | 4,166.0000 | 103,700,000 | 33.33% | 0.00% |
| Feb. 12, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | A | Restricted Stock Unit | 8022 | $0.00 | 8,022.0000 | 103,700,000 | 9999.99% | 0.01% |
| Feb. 12, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | A | Stock Option | 42805 | $0.00 | 42,805.0000 | 103,700,000 | 9999.99% | 0.04% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 1056 | $116.71 | 44,689.0000 | 103,700,000 | 2.31% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 2083 | $0.00 | 44,882.0000 | 103,700,000 | 4.87% | 0.00% |
| Feb. 13, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 1961 | $0.00 | 45,745.0000 | 103,700,000 | 4.48% | 0.00% |
| Feb. 10, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 980 | $118.31 | 42,799.0000 | 103,700,000 | 2.24% | 0.00% |
| Feb. 8, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 1860 | $0.00 | 43,779.0000 | 103,700,000 | 4.44% | 0.00% |
| Feb. 8, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Restricted Stock Unit | 1860 | $0.00 | 0.0000 | 103,700,000 | 100.00% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Restricted Stock Unit | 2294 | $0.00 | 2,294.0000 | 103,700,000 | 50.00% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 2294 | $0.00 | 43,126.0000 | 103,700,000 | 5.62% | 0.00% |
| Jan. 31, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 1207 | $152.94 | 41,919.0000 | 103,700,000 | 2.80% | 0.00% |
| Dec. 10, 2024 | aTYR PHARMA INC | $ATYR | BENEVICH ERIC | Not found | A | Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| April 15, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 12587 | $133.36 | 40,778.0000 | 101,000,000 | 23.59% | 0.01% |
| April 15, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Non-Qualified Stock Option | 12587 | $81.05 | 0.0000 | 101,000,000 | 100.00% | 0.01% |
| April 15, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Non-Qualified Stock Option | 7231 | $81.49 | 26,292.0000 | 101,000,000 | 21.57% | 0.01% |
| April 15, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 7231 | $81.49 | 48,009.0000 | 101,000,000 | 17.73% | 0.01% |
| April 15, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 7231 | $133.36 | 40,778.0000 | 101,000,000 | 15.06% | 0.01% |
| April 15, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 12587 | $81.05 | 53,365.0000 | 101,000,000 | 30.87% | 0.01% |
| March 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Non-Qualified Stock Option | 5479 | $79.02 | 33,881.0000 | 101,000,000 | 13.92% | 0.01% |
| March 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 5479 | $79.02 | 46,257.0000 | 101,000,000 | 13.44% | 0.01% |
| March 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 5479 | $139.38 | 40,778.0000 | 101,000,000 | 11.84% | 0.01% |
| March 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 69521 | $81.05 | 110,299.0000 | 101,000,000 | 170.49% | 0.07% |
| March 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 69521 | $139.38 | 40,778.0000 | 101,000,000 | 63.03% | 0.07% |
| March 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Non-Qualified Stock Option | 69521 | $81.05 | 12,587.0000 | 101,000,000 | 84.67% | 0.07% |
| Feb. 28, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Non-Qualified Stock Option | 53143 | $43.24 | 0.0000 | 101,000,000 | 100.00% | 0.05% |
| Feb. 28, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Non-Qualified Stock Option | 21857 | $79.02 | 39,360.0000 | 101,000,000 | 35.70% | 0.02% |
| Feb. 28, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 21857 | $134.69 | 40,616.0000 | 101,000,000 | 34.99% | 0.02% |
| Feb. 28, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 21857 | $79.02 | 62,473.0000 | 101,000,000 | 53.81% | 0.02% |
| Feb. 28, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 53143 | $134.69 | 40,616.0000 | 101,000,000 | 56.68% | 0.05% |
| Feb. 28, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 53143 | $43.24 | 93,759.0000 | 101,000,000 | 130.84% | 0.05% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 1098 | $133.01 | 40,616.0000 | 101,000,000 | 2.63% | 0.00% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | A | Restricted Stock Unit | 7846 | $0.00 | 7,846.0000 | 101,000,000 | 9999.99% | 0.01% |
| Feb. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | A | Stock Option | 39426 | $0.00 | 39,426.0000 | 101,000,000 | 9999.99% | 0.04% |
| Feb. 6, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 1280 | $142.12 | 38,751.0000 | 101,000,000 | 3.20% | 0.00% |
| Feb. 8, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 980 | $134.19 | 39,631.0000 | 101,000,000 | 2.41% | 0.00% |
| Jan. 31, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 1207 | $140.78 | 37,601.0000 | 101,000,000 | 3.11% | 0.00% |
| Aug. 21, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 1600 | $107.40 | 36,436.0000 | 98,900,000 | 4.21% | 0.00% |
| Feb. 13, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | A | Restricted Stock Unit | 8332 | $0.00 | 8,332.0000 | 98,900,000 | 9999.99% | 0.01% |
| Feb. 13, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | A | Stock Option | 51782 | $0.00 | 51,782.0000 | 98,900,000 | 9999.99% | 0.05% |
| Feb. 8, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 980 | $104.12 | 34,381.0000 | 98,900,000 | 2.77% | 0.00% |
| Feb. 7, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 15360 | $102.42 | 33,501.0000 | 98,900,000 | 31.44% | 0.02% |
| Feb. 7, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 2030 | $102.29 | 19,705.0000 | 98,900,000 | 9.34% | 0.00% |
| Feb. 6, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 1280 | $105.63 | 17,879.0000 | 98,900,000 | 6.68% | 0.00% |
| Jan. 31, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 1207 | $109.95 | 16,729.0000 | 98,900,000 | 6.73% | 0.00% |
| Jan. 6, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Common Stock | 400 | $43.24 | 16,043.0000 | 98,900,000 | 2.56% | 0.00% |
| Jan. 6, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | S | Common Stock | 400 | $125.00 | 15,643.0000 | 98,900,000 | 2.49% | 0.00% |
| Jan. 6, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | BENEVICH ERIC | Chief Commercial Officer | M | Non-Qualified Stock Option | 400 | $43.24 | 53,143.0000 | 98,900,000 | 0.75% | 0.00% |